Latest Earnings Results: Q3 '26
Estimated EPS
$2.20
Reported EPS
$2.66
Surprise
+20.86%
Estimated Rev
$827.12M
Reported Rev
$874.5M
Surprise
+5.73%
• Reported GAAP EPS of $2.66 up 35.71% YoY • Reported revenue of $874.5M up 8.69% YoY • West Pharmaceutical Services increased full-year 2026 net sales guidance to $3.41B to $3.42B and adjusted-diluted EPS guidance to $9.38 to $9.48, both increased from prior guidance.
Bullish Takeaway
West Pharmaceutical Services HVP Components sales increased 19.7% and accounted for 53% of Q3 2026 net sales; full-year guidance increased, and adjusted operating profit margin was 25.3% versus 21.1%.
Bearish Takeaway
West Pharmaceutical Services reported West Vantage sales declined 7.3%, Generics organic sales declined 4.5%, and no additional SmartDose 3.5mL sales are expected for the remainder of 2026.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | $2.29 | -- | -- | N/A |
Q3 '26 | $2.20 | $2.66 | 20.86% | BEAT |
Q2 '26 | $2.08 | $2.37 | 13.86% | BEAT |
Q1 '26 | $1.68 | $2.13 | 26.94% | BEAT |
Q4 '25 | $1.83 | $2.04 | 11.62% | BEAT |